This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 07:25, 15 October 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:25, 15 October 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report...)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Combination of | |
|---|---|
| Simvastatin | hypolipidemic statin |
| Sitagliptin | antidiabetic DPP-4 inhibitor |
| Clinical data | |
| Trade names | Juvisync |
| (verify) | |
Simvastatin/sitagliptin is a fixed-dose combination drug consisting of sitagliptin and simvastatin. Sitagliptin is used to treat for type 2 diabetes and simvastatin is used to treat hypercholesterolemia. These two disorders commonly occur in patients at the same time, and have been typically treated with administration of these two drugs in separate tablets. The combination was approved in 2011 and is marketed as Juvisync by Merck.
References
- "FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin". Forbes. October 7, 2011.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |